GlassScriptPhysician profile
Trellis H Baker
NPI 1841213659
$3,666.52
in general payments reported to CMS, 2019-2025
33 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $366 · 2021: $683 · 2022: $634 · 2023: $754 · 2024: $446 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,665.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.75 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $640.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $248.16 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $240.23 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $224.15 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.62 | 2020-2021 | |
| Corium, LLC | $168.67 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $139.61 | 2021-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $136.53 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $128.05 | 2020-2025 | Mounjaro, Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $75.39 | 2022 | |
| Allergan, INC. | $56.85 | 2020 | |
| Adlon Therapeutics L.P. | $56.17 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $39.31 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $38.52 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $38.34 | 2019-2020 | |
| Lundbeck LLC | $38.24 | 2025 | Rexulti |
| Dexcom, INC. | $36.01 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $32.98 | 2019-2020 | |
| Boston Scientific Corporation | $24.41 | 2025 | General - Pain Management |
| Collegium Pharmaceutical, INC. | $20.04 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.53 | 2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $18.38 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $18.37 | 2022 | |
| Alfasigma USA, INC. | $17.41 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.05 | 2021 | |
| Eisai INC. | $15.95 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.81 | 2022 | |
| Hikma Pharmaceuticals USA | $15.02 | 2024 | Ryaltris |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2020 | |
| Sanofi Pasteur INC. | $14.17 | 2019 | |
| Neos Therapeutics, LP | $14.06 | 2020 | |
| Ethicon US, LLC | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trellis Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.